Literature DB >> 17760804

CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.

Shaun Willimott1, Maria Baou, Kikkeri Naresh, Simon D Wagner.   

Abstract

Chronic lymphocytic leukaemia cells survive and proliferate in patients but rapidly die in culture. The microenvironment that sustains leukaemic cells in vivo contains both stromal cell elements and T cells. We defined changes in Bcl-2 family protein expression on culture with CD40 ligand (CD154) expressed on mouse fibroblast L cells, and interleukin-4 (IL-4; CD154/IL-4 system): conditions that support survival and proliferation. Unexpectedly, Bcl-2 protein expression decreased whilst pro-survival Bcl-x(L) (as well as A1 and Mcl-1) increased. However, the CD154-L cell/IL-4 system also increased the pro-apoptotic proteins, Bid and Noxa, suggesting that an increased pool of pro-survival factors and not the effects of a single protein mediate survival. Most pro-apoptotic proteins were not induced in drug or spontaneous apoptosis, but expression of Bcl-x(S), a pro-apoptotic BCL2L1 isoform, was associated with cell death. This was post-transcriptionally controlled, and, therefore, alternative splicing at the Bcl-x locus appears to have a role in the regulation of chronic lymphocytic leukaemia (CLL) cell survival. This study demonstrated a switch in pro-survival proteins associated with the transition from quiescence to CD154-driven proliferation. CLL therapies targeting Bcl-2 may need to be modified to antagonize proliferation centre-specific pro-survival proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17760804     DOI: 10.1111/j.1365-2141.2007.06717.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.

Authors:  G Tsirakis; C A Pappa; F E Psarakis; M Fragioudaki; C Tsioutis; E Stavroulaki; A Boula; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

2.  miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells.

Authors:  Shaun Willimott; Simon D Wagner
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

3.  17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.

Authors:  Erin Hertlein; Amy J Wagner; Jeffrey Jones; Thomas S Lin; Kami J Maddocks; William H Towns; Virginia M Goettl; Xiaoli Zhang; David Jarjoura; Chelsey A Raymond; Derek A West; Carlo M Croce; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

Review 4.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

5.  Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.

Authors:  Viralkumar Patel; Lisa S Chen; William G Wierda; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2013-09-10

Review 6.  The platelet as an immune cell-CD40 ligand and transfusion immunomodulation.

Authors:  Neil Blumberg; Sherry L Spinelli; Charles W Francis; Mark B Taubman; Richard P Phipps
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

7.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Authors:  Sina Oppermann; Jarkko Ylanko; Yonghong Shi; Santosh Hariharan; Christopher C Oakes; Patrick M Brauer; Juan C Zúñiga-Pflücker; Brian Leber; David E Spaner; David W Andrews
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

8.  Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.

Authors:  Darcy J P Bates; Alexey V Danilov; Christopher H Lowrey; Alan Eastman
Journal:  Mol Cancer Ther       Date:  2013-05-30       Impact factor: 6.261

9.  Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.

Authors:  N Purroy; P Abrisqueta; J Carabia; C Carpio; E Calpe; C Palacio; J Castellví; M Crespo; F Bosch
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 12.883

10.  Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12.

Authors:  Alison M McCaig; Emilio Cosimo; Michael T Leach; Alison M Michie
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.